CoChat

High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population – first results from a cohort study in Southern Sweden

Open access
Björk, Jonas, Inghammar, Malin, Moghaddassi, Mahnaz, Rasmussen, Magnus, Malmqvist, Ulf, Kahn, Fredrik · 2022 · Infectious Diseases

Published version of a preprint

Cited by 51

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Vaccine effectiveness against COVID-19 needs to be assessed in diverse real-world population settings. METHODS: A cohort study of 805,741 residents in Skåne county, Southern Sweden, aged 18-64 years, of whom 26,587 received at least one dose of the BNT162b2 vaccine. Incidence rates of COVID-19 were estimated in sex- and age-adjusted analysis and stratified in two-week periods with substantial community spread of the disease. RESULTS: The estimated vaccine effectiveness in preventing infection ≥7 days after second dose was 86% (95% CI 72-94%) but only 42% (95% CI 14-63%) ≥14 days after a single dose. No difference in vaccine effectiveness was observed between females and males. Having a prior positive test was associated with 91% (95% CI 85-94%) effectiveness against new infection among the unvaccinated. CONCLUSION: A satisfactory effectiveness of BNT162b2 after the second dose was suggested, but with possibly substantially lower effect before the second dose.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/23744235.2021.1982144

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 4

  1. 2021, Statistik om SARS-CoV-2 virusvarianter av särskild betydelse (in Swedish)
  2. Hunter PR, Brainard J. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of ‘real-world’ vaccination outcomes from Israel. medRxiv 2021:2021.02.01.21250957. · DOI · Paper page
  3. Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of first dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. SSRN 2021. · DOI · Paper page
  4. Hall V, Foulkes S, Charlett A, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. medRxiv 2021. DOI:10.1101/2021.01.13.21249642 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Björk, J., Inghammar, M., Moghaddassi, M., Rasmussen, M., Malmqvist, U., & Kahn, F.
Venue
Infectious Diseases
Published
2021-09-29
Volume
54
Issue
2
Pages
128-133
ISSN
  • 0036-5548 (ISSN-L)
  • 2374-4235
  • 2374-4243
OpenAlex
W3202213294
Cited by
51
References
7
FWCI
3.70
Type
journal article
Language
en
Open access
hybrid
Funders
Lund University (2019-00198)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population – first results from a cohort study in Southern Sweden. https://app.cochat.ai/papers/10.1080/23744235.2021.1982144
The paper
Björk, J., Inghammar, M., Moghaddassi, M., Rasmussen, M., Malmqvist, U., & Kahn, F. (2022). High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population – first results from a cohort study in Southern Sweden. Infectious Diseases. https://doi.org/10.1080/23744235.2021.1982144

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.